Proteases as modulators of tumor-stromal interaction: Primary tumors to bone metastases

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1785, Issue 2, 2008, Pages 85-95

  Wilson, Thomas J ^a   Singh, Rakesh K ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Bone metastasis; Proteases; Tumor progression; Tumor stromal interaction

Indexed keywords

CATHEPSIN; CATHEPSIN B; CATHEPSIN F; CATHEPSIN H; CATHEPSIN L; CATHEPSIN S; CATHEPSIN V; CATHEPSIN W; CATHEPSIN X; COLLAGENASE 3; DIPEPTIDYL PEPTIDASE I; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 16; MATRIX METALLOPROTEINASE 17; MATRIX METALLOPROTEINASE 19; MATRIX METALLOPROTEINASE 20; PROTEINASE; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; UNCLASSIFIED DRUG;

BONE METASTASIS; BREAST CANCER; CANCER CELL; CELL COMMUNICATION; CELL INTERACTION; ENZYME ACTIVITY; HUMAN; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; STROMA CELL; TUMOR GROWTH;

BONE NEOPLASMS; BREAST NEOPLASMS; CATHEPSINS; CELL COMMUNICATION; HUMANS; MALE; MATRIX METALLOPROTEINASES; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; PEPTIDE HYDROLASES; PROSTATIC NEOPLASMS; STROMAL CELLS;

EID: 41949122740     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2007.11.001     Document Type: Review

References (78)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007 CA. Cancer J. Clin. 57 (2007) 43-66
2. Bubendorf L., Schopfer A., Wagner U., Sauter G., Moch H., Willi N., Gasser T.C., and Mihatsch M.J. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum. Pathol 31 (2000) 578-583
3. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2 (2002) 584-593
4. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
5. Goltzman D., Karaplis A.C., Kremer R., and Rabbani S.A. Molecular basis of the spectrum of skeletal complications of neoplasia. Cancer 88 (2000) 2903-2908
6. Roudier M.P., Corey E., True L.D., Hiagno C.S., Ott S.M., and Vessell R.L. Histological, immunophenotypic and histomorphometric characterization of prostate cancer bone metastases. Cancer Treat. Res 118 (2004) 311-339
7. Shimazaki J., Higa T., Akimoto S., Masai M., and Isaka S. Clinical course of bone metastasis from prostatic cancer following endocrine therapy: examination with bone X-ray. Adv. Exp. Med. Biol 324 (1992) 269-275
8. Roodman G.D. Mechanisms of bone metastasis. N. Engl. J. Med 350 (2004) 1655-1664
9. Birkedal-Hansen H. Catabolism and turnover of collagens: collagenases. Methods Enzymol 144 (1987) 140-171
10. Van Wart H.E., and Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc. Natl. Acad. Sci. U. S. A 87 (1990) 5578-5582
11. McCawley L.J., and Matrisian L.M. Matrix metalloproteinases: they're not just for matrix anymore!. Curr. Opin. Cell Biol 13 (2001) 534-540
12. Nelson A.R., Fingleton B., Rothenberg M.L., and Matrisian L.M. Matrix metalloproteinases: biologic activity and clinical implications. J. Clin. Oncol 18 (2000) 1135-1149
13. Nagase H., Visse R., and Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res 69 (2006) 562-573
14. Woessner Jr. J.F., and Nagase H. Matrix Metalloproteinases and TIMPs. 1st ed. (2000), Oxford University Press, New York Anonymous
15. Strickland D.K., Ashcom J.D., Williams S., Burgess W.H., Migliorini M., and Argraves W.S. Sequence identity between the alpha 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor. J. Biol. Chem 265 (1990) 17401-17404
16. Mohamed M.M., and Sloane B.F. Cysteine cathepsins: multifunctional enzymes in cancer. Nat. Rev. Cancer 6 (2006) 764-775
17. Nomura T., and Katunuma N. Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells. J. Med. Invest 52 (2005) 1-9
18. Lochter A., Galosy S., Muschler J., Freedman N., Werb Z., and Bissell M.J. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J. Cell Biol 139 (1997) 1861-1872
19. Seeley S., Covic L., Jacques S.L., Sudmeier J., Baleja J.D., and Kuliopulos A. Structural basis for thrombin activation of a protease-activated receptor: inhibition of intramolecular liganding. Chem. Biol 10 (2003) 1033-1041
20. Cooper C.R., Chay C.H., Gendernalik J.D., Lee H.L., Bhatia J., Taichman R.S., McCauley L.K., Keller E.T., and Pienta K.J. Stromal factors involved in prostate carcinoma metastasis to bone. Cancer 97 (2003) 739-747
21. Boire A., Covic L., Agarwal A., Jacques S., Sherifi S., and Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120 (2005) 303-313
22. Monsky W.L., Mouta C.C., uzuki Y.T., Gohongi T., Fukumura D., and Jain R.K. Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: mammary fat pad versus cranial tumors. Clin. Cancer Res 8 (2002) 1008-1013
23. Egeblad M., and Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2 (2002) 161-174
24. Cukierman E., Pankov R., Stevens D.R., and Yamada K.M. Taking cell-matrix adhesions to the third dimension. Science 294 (2001) 1708-1712
25. Hotary K.B., Allen E.D., Brooks P.C., Datta N.S., Long M.W., and Weiss S.J. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 114 (2003) 33-45
26. Nakahara H., Howard L., Thompson E.W., Sato H., Seiki M., Yeh Y., and Chen W.T. Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion. Proc. Natl. Acad. Sci. U. S. A 94 (1997) 7959-7964
27. Remacle A.G., Rozanov D.V., Fugere M., Day R., and Strongin A.Y. Furin regulates the intracellular activation and the uptake rate of cell surface-associated MT1-MMP. Oncogene 25 (2006) 5648-5655
28. Artym V.V., Zhang Y., Seillier-Moiseiwitsch F., Yamada K.M., and Mueller S.C. Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res 66 (2006) 3034-3043
29. Gotte M., and Yip G.W. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res 66 (2006) 10233-10237
30. Sanderson R.D., Yang Y., Kelly T., MacLeod V., Dai Y., and Theus A. Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies. J. Cell Biochem 96 (2005) 897-905
31. Sanderson R.D., Yang Y., Suva L.J., and Kelly T. Heparan sulfate proteoglycans and heparanase-partners in osteolytic tumor growth and metastasis. Matrix Biol 23 (2004) 341-352
32. Naor D., Sionov R.V., and Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv. Cancer Res 71 (1997) 241-319
33. Kajita M., Itoh Y., Chiba T., Mori H., Okada A., Kinoh H., and Seiki M. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J. Cell Biol 153 (2001) 893-904
34. Wolf M., Clark-Lewis I., Buri C., Langen H., Lis M., and Mazzucchelli L. Cathepsin D specifically cleaves the chemokines macrophage inflammatory protein-1 alpha, macrophage inflammatory protein-1 beta, and SLC that are expressed in human breast cancer. Am. J. Pathol 162 (2003) 1183-1190
35. Kim J., Yu W., Kovalski K., and Ossowski L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 94 (1998) 353-362
36. Steinhoff M., Buddenkotte J., Shpacovitch V., Rattenholl A., Moormann C., Vergnolle N., Luger T.A., and Hollenberg M.D. Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr. Rev 26 (2005) 1-43
37. Even-Ram S., Uziely B., Cohen P., Grisaru-Granovsky S., Maoz M., Ginzburg Y., Reich R., Vlodavsky I., and Bar-Shavit R. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat. Med 4 (1998) 909-914
38. Camerer E., Qazi A.A., Duong D.N., Cornelissen I., Advincula R., and Coughlin S.R. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 104 (2004) 397-401
39. Im J.H., Fu W., Wang H., Bhatia S.K., Hammer D.A., Kowalska M.A., and Muschel R.J. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res 64 (2004) 8613-8619
40. Goerge T., Barg A., Schnaeker E.M., Poppelmann B., Shpacovitch V., Rattenholl A., Maaser C., Luger T.A., Steinhoff M., and Schneider S.W. Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation. Cancer Res 66 (2006) 7766-7774
41. Noel A.C., Lefebvre O., Maquoi E., VanHoorde L., Chenard M.P., Mareel M., Foidart J.M., Basset P., and Rio M.C. Stromelysin-3 expression promotes tumor take in nude mice. J. Clin. Invest 97 (1996) 1924-1930
42. Kaplan R.N., Riba R.D., Zacharoulis S., Bramley A.H., Vincent L., Costa C., MacDonald D.D., Jin D.K., Shido K., Kerns S.A., Zhu Z., Hicklin D., Wu Y., Port J.L., Altorki N., Port E.R., Ruggero D., Shmelkov S.V., Jensen K.K., Rafii S., and Lyden D. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438 (2005) 820-827
43. Kaplan R.N., Psaila B., and Lyden D. Bone marrow cells in the 'pre-metastatic niche': within bone and beyond. Cancer Metastasis Rev 25 (2006) 521-529
44. Zheng Y., Zhou H., Brennan K., Blair J.M., Modzelewski J.R., Seibel M.J., and Dunstan C.R. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone 40 (2007) 471-478
45. Iguchi H. [Molecular mechanism and potential targets for bone metastasis]. Gan To Kagaku Ryoho 34 (2007) 1-10
46. Brown J.E., Neville-Webbe H., and Coleman R.E. The role of bisphosphonates in breast and prostate cancers. Endocr. Relat Cancer 11 (2004) 207-224
47. Varghese S. Matrix metalloproteinases and their inhibitors in bone: an overview of regulation and functions. Front Biosci. 11 2949-66 (2006) 2949-2966
48. Keller E.T. The role of osteoclastic activity in prostate cancer skeletal metastases. Drugs Today (Barc.) 38 (2002) 91-102
49. Teronen O., Konttinen Y.T., Lindqvist C., Salo T., Ingman T., Lauhio A., Ding Y., Santavirta S., Valleala H., and Sorsa T. Inhibition of matrix metalloproteinase-1 by dichloromethylene bisphosphonate (clodronate). Calcif. Tissue Int 61 (1997) 59-61
50. Yoneda T., Sasaki A., Dunstan C., Williams P.J., Bauss F., De Clerck Y.A., and Mundy G.R. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J. Clin. Invest 99 (1997) 2509-2517
51. Zou Z., Anisowicz A., Hendrix M.J., Thor A., Neveu M., Sheng S., Rafidi K., Seftor E., and Sager R. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 263 (1994) 526-529
52. Sheng S., Carey J., Seftor E.A., Dias L., Hendrix M.J., and Sager R. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc. Natl. Acad. Sci. U. S. A 93 (1996) 11669-11674
53. Sheng S., Pemberton P.A., and Sager R. Production, purification, and characterization of recombinant maspin proteins. J. Biol. Chem 269 (1994) 30988-30993
54. Biliran Jr. H., and Sheng S. Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin. Cancer Res 61 (2001) 8676-8682
55. Cher M.L., Biliran Jr. H.R., Bhagat S., Meng Y., Che M., Lockett J., Abrams J., Fridman R., Zachareas M., and Sheng S. Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis. Proc. Natl. Acad. Sci. U. S. A 100 (2003) 7847-7852
56. Dong Z., Bonfil R.D., Chinni S., Deng X., Trindade Filho J.C., Bernardo M., Vaishampayan U., Che M., Sloane B.F., Sheng S., Fridman R., and Cher M.L. Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. Am. J. Pathol 166 (2005) 1173-1186
57. Nemeth J.A., Yousif R., Herzog M., Che M., Upadhyay J., Shekarriz B., Bhagat S., Mullins C., Fridman R., and Cher M.L. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J. Natl. Cancer Inst 94 (2002) 17-25
58. Ishibashi O., Niwa S., Kadoyama K., and Inui T. MMP-9 antisense oligodeoxynucleotide exerts an inhibitory effect on osteoclastic bone resorption by suppressing cell migration. Life Sci 79 (2006) 1657-1660
59. Lu Y., Cai Z., Xiao G., Keller E.T., Mizokami A., Yao Z., Roodman G.D., and Zhang J. Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. Cancer Res 67 (2007) 3646-3653
60. Bendre M.S., Margulies A.G., Walser B., Akel N.S., Bhattacharrya S., Skinner R.A., Swain F., Ramani V., Mohammad K.S., Wessner L.L., Martinez A., Guise T.A., Chirgwin J.M., Gaddy D., and Suva L.J. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-{kappa}B ligand pathway. Cancer Res 65 (2005) 11001-11009
61. Lynch C.C., Hikosaka A., Acuff H.B., Martin M.D., Kawai N., Singh R.K., Vargo-Gogola T.C., Begtrup J.L., Peterson T.E., Fingleton B., Shirai T., Matrisian L.M., and Futakuchi M. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 7 (2005) 485-496
62. Mengshol J.A., Vincenti M.P., and Brinckerhoff C.E. IL-1 induces collagenase-3 (MMP-13) promoter activity in stably transfected chondrocytic cells: requirement for Runx-2 and activation by p38 MAPK and JNK pathways. Nucleic Acids Res 29 (2001) 4361-4372
63. Koeneman K.S., Yeung F., and Chung L.W. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 39 (1999) 246-261
64. Cooper C.R., and Pienta K.J. Cell adhesion and chemotaxis in prostate cancer metastasis to bone: a minireview. Prostate Cancer Prostatic Dis 3 (2000) 6-12
65. Doerr M.E., and Jones J.I. The roles of integrins and extracellular matrix proteins in the insulin-like growth factor I-stimulated chemotaxis of human breast cancer cells. J. Biol. Chem 271 (1996) 2443-2447
66. Yoneda T., and Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem. Biophys. Res. Commun 328 (2005) 679-687
67. Yu Q., and Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14 (2000) 163-176
68. Yin J.J., Selander K., Chirgwin J.M., Dallas M., Grubbs B.G., Wieser R., Massague J., Mundy G.R., and Guise T.A. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest 103 (1999) 197-206
69. Ishikawa T., Kamiyama M., Tani-Ishii N., Suzuki H., Ichikawa Y., Hamaguchi Y., Momiyama N., and Shimada H. Inhibition of osteoclast differentiation and bone resorption by Cathepsin K antisense oligonucleotides. Mol. Carcinog 32 (2001) 84-91
70. Stern P.H., Tatrai A., Semler D.E., Lee S.K., Lakatos P., Strieleman P.J., Tarjan G., and Sanders J.L. Endothelin receptors, second messengers, and actions in bone. J. Nutr. 125 (1995) 2028S-2032S
71. Takuwa Y., Masaki T., and Yamashita K. The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae. Biochem. Biophys. Res. Commun 170 (1990) 998-1005
72. Guise T.A., Yin J.J., and Mohammad K.S. Role of endothelin-1 in osteoblastic bone metastases. Cancer 97 (2003) 779-784
73. Chiao J.W., Moonga B.S., Yang Y.M., Kancherla R., Mittelman A., Wu-Wong J.R., and Ahmed T. Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br. J. Cancer 83 (2000) 360-365
74. Conover C.A., Perry J.E., and Tindall D.J. Endogenous Cathepsin D-mediated hydrolysis of insulin-like growth factor-binding proteins in cultured human prostatic carcinoma cells. J. Clin. Endocrinol. Metab 80 (1995) 987-993
75. Koutsilieris M., Frenette G., Lazure C., Lehoux J.G., Govindan M.V., and Polychronakos C. Urokinase-type plasminogen activator: a paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases. Anticancer Res 13 (1993) 481-486
76. Koutsilieris M., and Polychronakos C. Proteinolytic activity against IGF-binding proteins involved in the paracrine interactions between prostate adenocarcinoma cells and osteoblasts. Anticancer Res 12 (1992) 905-910
77. Le B.G., Aubin P., Soliman H., Ropiquet F., Villette J.M., Berthon P., Creminon C., Cussenot O., and Fiet J. Upregulation of endothelin 1 and its precursor by IL-1beta, TNF-alpha, and TGF-beta in the PC3 human prostate cancer cell line. Cytokine 11 (1999) 157-162
78. Lopez-Otin C., and Matrisian L.M. Emerging roles of proteases in tumour suppression. Nat. Rev., Cancer 7 (2007) 800-808